Barbara Grube, MD
Berlin, Germany
NCT Number: NCT01435278
To date, there is no clinical evidence on the efficacy and safety of Glucosanol in maintaining weight loss beyond the study duration of 12 weeks. The rationale for this open-label study is to assess the efficacy in preventing regain of loss body weight and safety of Glucosanol in subjects who are overweight or obese over a longer period after the initial weight loss.
Looking for future studies?
Notify Me18 year–60 year
All sexes
Interventional
Phase 4
Berlin, Germany
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
2 tablets taken 3 times a day.
Time frame: 24 weeks
Measured in kg using a calibrated scale
Time frame: 24 weeks
Changes from baseline to end of study
Time frame: 24 weeks
Changes from baseline to end of study
Time frame: 24 weeks
Changes from baseline to end of study
Time frame: 24 weeks
The Control of Eating Questionnaire (COEQ) is used
Time frame: 24 weeks
A 4-point categorical scale is used
Time frame: 24 weeks
A 4-point categorical scale is used
Time frame: 24 weeks
Done at baseline and end of study
Time frame: 24 weeks
Done at baseline and end of study
Time frame: 24 weeks
Measured in mm Hg
Time frame: 24 weeks
A 4-point categorical scale is used.
Time frame: 24 weeks
A 4-point categorical scale is used
Time frame: 24 weeks
All reported adverse events, regardless of causality, will be recorded in the source documents and case report forms
InQpharm Group
Industry
Open-label Clinical Investigation to Evaluate the Safety and Efficacy of Glucosanol in Maintaining Body Weight Loss in Overweight and Obese Subjects
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07513610
Body Weight, Nutrition Disorders
Ankara, Sıhhiye, Turkey (Türkiye)
View Trial DetailsNCT02736669
Behavior, Body Weight
Birmingham, Alabama, United States
View Trial DetailsNCT05056376
Behavior, Body Weight
Baltimore, Maryland, United States
View Trial DetailsNCT05981508
Behavior, Behavior, Animal
Chapel Hill, North Carolina, United States
View Trial Details